Publications by authors named "Ortego N"
A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.
Int J Technol Assess Health Care
August 2022
Objectives: Our aim was to assess the value of nintedanib for non-idiopathic progressive fibrosing interstitial lung disease (non-IPF PF-ILD) and systemic sclerosis-associated ILD (SSc-ILD) in the Spanish context, using a multi-criteria decision analysis (MCDA).
Methods: Following an adaptation of the Evidence and Value: Impact on DEcision Making (EVIDEM) MCDA methodology, the estimated value of nintedanib was obtained by means of an additive linear model that combined individual weights (100-points distribution) of criteria with the individual scoring of nintedanib in each criterion for every indication, assigned by a multidisciplinary committee of twelve clinicians, patients, pharmacists, and decision-makers. To assess the reproducibility, an alternative weighting method was applied, as well as a re-test of weights and scores at a different moment of time.
Article Synopsis
- The study evaluated the effectiveness and safety of biologic therapy (BT) in patients with neurobehçet's disease (NBD) who did not respond to glucocorticoids and conventional immunosuppressive drugs.
- Conducted as a national, multicenter, open-label study, it involved 41 patients and focused on clinical remission, glucocorticoid reduction, and lab parameter improvements as outcomes.
- Results showed that after six months, over half of the patients achieved complete remission, there was a significant reduction in prednisone dosage, and 90.2% maintained at least partial remission after an average follow-up of nearly 58 months, highlighting BT's effectiveness and moderate safety despite some adverse events.
Objective: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu's arteritis (TAK) in clinical practice.
Methods: A multicenter study of Caucasian patients with refractory TAK who received TCZ. The outcome variables were remission, glucocorticoid-sparing effect, improvement in imaging techniques, and adverse events.
Article Synopsis
- Denosumab is a medication for postmenopausal osteoporosis, but stopping it can lead to a rapid decline in bone density and increase the risk of multiple vertebral fractures (MVF).
- This study analyzed 56 postmenopausal women who suffered MVFs after discontinuing denosumab, focusing on their clinical and biochemical profiles and identifying factors linked to more fractures.
- Results showed 192 new vertebral fractures, with most patients having no prior fractures; the duration of denosumab use was the only significant factor tied to a higher number of fractures after stopping the drug.
Objectives: Rapid control of intraocular inflammation in non-infectious uveitis (NIU) is mandatory to avoid irreversible structural and functional damage. In this study, we assessed the efficacy and safety of intravenous methylprednisolone (IVMP) pulses in the treatment of NIU.
Methods: A retrospective case series of 112 patients who received IVMP for the treatment of NIU, either isolated or associated with different underlying diseases, was studied.
Article Synopsis
- - The study aims to improve the classification and treatment of systemic autoimmune diseases by identifying molecular clusters, moving beyond traditional clinical diagnosis methods.
- - Researchers analyzed blood samples from 955 patients and 267 healthy controls, discovering four distinct clusters: three linked to inflammatory responses and one related to low disease activity associated with healthy controls.
- - The findings suggest that these molecular clusters are stable over time and can aid in understanding disease mechanisms and improving treatment strategies, potentially changing how systemic autoimmune diseases are approached in clinical settings.
Objective: In a large series of White patients with refractory uveitis due to Behçet disease (BD) being treated with infliximab (IFX), we assessed (1) long-term efficacy and safety of IFX, and (2) IFX optimization when ocular remission was achieved.
Methods: Our multicenter study of IFX-treated patients with BD uveitis refractory to conventional immunosuppressant agents treated 103 patients/185 affected eyes with IFX as first biologic therapy in the following intervals: 3-5 mg/kg intravenous at 0, 2, 6, and then every 4-8 weeks. The main outcome variables were analyzed at baseline, first week, first month, sixth month, first year, and second year of IFX therapy.
Objectives: A potential point of concern among clinicians is whether results derived from the clinical trials can be reasonably applied or generalised to a definable group of patients seen in real world. It can be the case of the GiACTA study that is a phase III randomised controlled trial of tocilizumab (TCZ) in giant cell arteritis (GCA). To address this question, we compared the clinical features and the responses to TCZ from the GiACTA trial patients with those from a series of GCA seen in the daily clinical practice.
View Article and Find Full Text PDFArticle Synopsis
- Tocilizumab (TCZ) has been found to be effective for treating giant cell arteritis (GCA) in an observational study involving 134 patients, most of whom had previously received other treatments.
- After one month on TCZ, a significant 93.9% of patients showed clinical improvement, including notable reductions in CRP and ESR levels, alongside a decrease in anemia.
- Despite the positive outcomes, serious infections were observed more frequently than in prior clinical trials, particularly among patients taking higher doses of prednisone during the initial treatment phase.
Purpose: To assess efficacy, safety, and cost-effectiveness of adalimumab (ADA) therapy optimization in a large series of patients with uveitis due to Behçet disease (BD) who achieved remission after the use of this biologic agent.
Design: Open-label multicenter study of ADA-treated patients with BD uveitis refractory to conventional immunosuppressants.
Subjects: Sixty-five of 74 patients with uveitis due to BD, who achieved remission after a median ADA duration of 6 (range, 3-12) months.
Gene-level analysis of ImmunoChip or genome-wide association studies (GWAS) data has not been previously reported for systemic sclerosis (SSc, scleroderma). The objective of this study was to analyze genetic susceptibility loci in SSc at the gene level and to determine if the detected associations were shared in African-American and White populations, using data from ImmunoChip and GWAS genotyping studies. The White sample included 1833 cases and 3466 controls (956 cases and 2741 controls from the US and 877 cases and 725 controls from Spain) and the African American sample, 291 cases and 260 controls.
View Article and Find Full Text PDFObjectives: To assess the efficacy of tocilizumab (TCZ) in patients with Takayasu arteritis (TA).
Methods: Multicentre open-label retrospective study.
Results: Eight patients (all women) with a mean age of 34±16 years, median 36 years (range: 7-57) were assessed.
Objective: The aim of this study was to assess the efficacy of anti-TNF-α therapy in refractory uveitis due to Behçet's disease (BD).
Methods: We performed a multicentre study of 124 patients with BD uveitis refractory to conventional treatment including high-dose corticosteroids and at least one standard immunosuppressive agent. Patients were treated for at least 12 months with infliximab (IFX) (3-5 mg/kg at 0, 2 and 6 weeks and then every 4-8 weeks) or adalimumab (ADA) (usually 40 mg every 2 weeks).
Adalimumab for the treatment of Behçet's disease: experience in 19 patients.
Rheumatology (Oxford)
October 2012
Objective: To describe the experience of two tertiary Spanish centres (Hospital Clínico San Cecilio, Granada and Hospital Clínic, Barcelona) with the use of adalimumab for the treatment of severe clinical manifestations in patients with Behçet's disease (BD) in whom immunosuppressive therapy had failed.
Methods: Retrospective chart review from patients with BD treated with adalimumab in two specialized Spanish centres (Hospital Clínico San Cecilio, Granada and Hospital Clínic, Barcelona).
Results: From November 2006 to February 2011, 19 patients with BD were treated with adalimumab.
Objective: To evaluate adalimumab therapy in refractory uveitis.
Design: Prospective case series.
Participants: A total of 131 patients with refractory uveitis and intolerance or failure to respond to prednisone and at least 1 other systemic immunosuppressive drug participated.
Objectives: To analyse the safety and efficacy of the off-label use of rituximab in patients with severe, refractory systemic autoimmune diseases.
Methods: In 2006, the Study Group on Autoimmune Diseases of the Spanish Society of Internal Medicine created the BIOGEAS project, a multicenter study devoted to collecting data on the use of biological agents in adult patients with systemic autoimmune diseases refractory to standard therapies (failure of at least two immunosuppressive agents).
Results: One hundred and ninety-six patients with systemic autoimmune diseases treated with rituximab have been included in the Registry (158 women and 38 men, mean age 43 years).
Objectives: The TRAF1-C5 locus has recently been identified as a genetic risk factor for rheumatoid arthritis (RA). Since genetic risk factors tend to overlap with several autoimmune diseases, a study was undertaken to investigate whether this region is associated with type 1 diabetes (TID), celiac disease (CD), systemic sclerosis (SSc) and systemic lupus erythematosus (SLE).
Methods: The most consistently associated SNP, rs10818488, was genotyped in a total of 735 patients with T1D, 1049 with CD, 367 with SSc, 746 with SLE and 3494 ethnically- and geographically-matched healthy individuals.
We evaluated the influence of the hereditary make-up on the development of systemic lupus erythematosus (SLE) in two ethnic groups [Gypsy and white Caucasian Mediterranean (WCM) populations], living in the same geographic area. We compared 81 WCM and 25 Gypsy patients with SLE. The control group consisted of 185 healthy unrelated individuals, 105 WC and 80 Gypsies.
View Article and Find Full Text PDF